BR112016003441A2 - anticorpo isolado ou fragmento de ligação de antígeno do mesmo, conjugado de droga para anticorpo, métodos para eliminar células que expressam baixos níveis de prlr e de um receptor de citocina classe i e para inibir ou atenuar crescimento de tumor, e, composição farmacêutica - Google Patents

anticorpo isolado ou fragmento de ligação de antígeno do mesmo, conjugado de droga para anticorpo, métodos para eliminar células que expressam baixos níveis de prlr e de um receptor de citocina classe i e para inibir ou atenuar crescimento de tumor, e, composição farmacêutica

Info

Publication number
BR112016003441A2
BR112016003441A2 BR112016003441A BR112016003441A BR112016003441A2 BR 112016003441 A2 BR112016003441 A2 BR 112016003441A2 BR 112016003441 A BR112016003441 A BR 112016003441A BR 112016003441 A BR112016003441 A BR 112016003441A BR 112016003441 A2 BR112016003441 A2 BR 112016003441A2
Authority
BR
Brazil
Prior art keywords
antibodies
prlr
antibody
antigen binding
binding fragment
Prior art date
Application number
BR112016003441A
Other languages
English (en)
Other versions
BR112016003441B1 (pt
Inventor
Delfino Frank
Thurston Gavin
Kirshner Jessica
Kelly Marcus
Papadopoulos Nicholas
Nittoli Thomas
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016003441(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112016003441A2 publication Critical patent/BR112016003441A2/pt
Publication of BR112016003441B1 publication Critical patent/BR112016003441B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente descrição provê anticorpos que se ligam ao receptor de prolactina (prlr), e métodos para usar os mesmos. de acordo com certas modalidades, os anticorpos da descrição se ligam ao prlr de humano com alta afinidade. em certas modalidades, a descrição inclui anticorpos que se ligam ao prlr e bloqueiam sinalização celular mediada por prolactina. em outras modalidades, a descrição inclui anticorpos que se ligam ao prlr, mas não bloqueiam sinalização celular mediada por prolactina. os anticorpos da descrição podem ser anticorpos totalmente humanos. a descrição inclui anticorpos anti-prlr conjugados com um agente citotóxico, radionuclídeo, ou outra fração detrimental para crescimento ou proliferação celular. os anticorpos da descrição são úteis para o tratamento de vários cânceres bem como outros distúrbios relacionados ao prlr. a presente descrição também inclui conjugados de droga para anticorpo compreendendo um anticorpo ou fragmento de ligação de antígeno do mesmo que se liga especificamente a um receptor de citocina classe i, em que o anticorpo ou fragmento de ligação de antígeno do mesmo é conjugado com um agente citotóxico.
BR112016003441-4A 2013-08-21 2014-08-20 Anticorpo isolado ou fragmento de ligação de antígeno do mesmo, conjugado de droga para anticorpo, usos dos mesmos, e, composição farmacêutica BR112016003441B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361868185P 2013-08-21 2013-08-21
US61/868,185 2013-08-21
US201462012440P 2014-06-16 2014-06-16
US62/012,440 2014-06-16
US201462026088P 2014-07-18 2014-07-18
US62/026,088 2014-07-18
PCT/US2014/051831 WO2015026907A1 (en) 2013-08-21 2014-08-20 Anti-prlr antibodies and uses thereof

Publications (2)

Publication Number Publication Date
BR112016003441A2 true BR112016003441A2 (pt) 2017-12-05
BR112016003441B1 BR112016003441B1 (pt) 2023-07-25

Family

ID=

Also Published As

Publication number Publication date
JP2020023511A (ja) 2020-02-13
JP6621412B2 (ja) 2019-12-18
US10683354B2 (en) 2020-06-16
AU2014308920A1 (en) 2016-03-03
PH12016500349A1 (en) 2016-05-16
UY35712A (es) 2015-03-27
US20180094066A1 (en) 2018-04-05
KR102343315B1 (ko) 2021-12-27
AU2014308920B2 (en) 2020-02-06
CL2016000376A1 (es) 2017-05-19
HK1220206A1 (zh) 2017-04-28
CA2920369A1 (en) 2015-02-26
TWI641620B (zh) 2018-11-21
US9302015B2 (en) 2016-04-05
MX370787B (es) 2020-01-06
US10106616B2 (en) 2018-10-23
IL243974B (en) 2018-06-28
US20150056221A1 (en) 2015-02-26
CA2920369C (en) 2023-03-14
US20190241667A1 (en) 2019-08-08
MX2016002150A (es) 2016-06-28
PH12016500349B1 (en) 2016-05-16
TW201542592A (zh) 2015-11-16
EA201600190A1 (ru) 2016-08-31
EP3036257B1 (en) 2019-10-16
EP3036257A1 (en) 2016-06-29
WO2015026907A1 (en) 2015-02-26
US20160251442A1 (en) 2016-09-01
US9688764B2 (en) 2017-06-27
IL243974A0 (en) 2016-04-21
NZ716612A (en) 2022-07-29
SG11201601211TA (en) 2016-03-30
JP2016532703A (ja) 2016-10-20
KR20160036630A (ko) 2016-04-04
CN105793286B (zh) 2021-01-12
MY179851A (en) 2020-11-18
CN105793286A (zh) 2016-07-20

Similar Documents

Publication Publication Date Title
PH12016500349A1 (en) Anti-prlr antibodies and uses thereof
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
CL2017001729A1 (es) Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20; y usos de los mismos.
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
NZ597694A (en) Anti-IGF antibodies
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
AR103867A1 (es) Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos
AR064360A1 (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
EA201171374A1 (ru) Антитела против cd100 и способы их применения
BR112015014751A2 (pt) anticorpos anti-tau humanos
BR112018009067A8 (pt) anticorpos anti-c5 e métodos de uso
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
BR112012013975B8 (pt) anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo
BR112022025295A2 (pt) Células natural killer modificadas geneticamente para imunoterapia do câncer direcionada a cd70
BRPI0817427A8 (pt) anticorpo anti-bst2
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61K 47/00 (2006.01), A61P 3

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2014, OBSERVADAS AS CONDICOES LEGAIS